This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lüscher-Firzlaff, J. Articles by Lüscher, B. Search for Related Content PubMed PubMed Citation Articles by Lüscher-Firzlaff, J. Articles by Lüscher, B.

The Human Trithorax Protein hASH2 Functions as an Oncoprotein

¹ Institut für Biochemie and ² Institut für Pathologie, Klinikum, RWTH Aachen University, Aachen, Germany; ³ Institut für Krebsforschung, Klinik für Innere Medizin I, Medizinische Universität Wien, Wien, Austria; and ⁴ GSF-Institut für Molekulare Immunologie, Munich, Germany

Requests for reprints: Bernhard Lüscher, Institut für Biochemie, Klinikum, RWTH Aachen University, Pauwelsstrasse 30, 52057 Aachen, Germany. Phone: 49-241-8088850; E-mail: luescher{at}rwth-aachen.de.

Key Words: transformation • MLL • Menin • transcription • methylation

Regulation of chromatin is an important aspect of controlling promoter activity and gene expression. Posttranslational modifications of core histones allow proteins associated with gene transcription to access chromatin. Closely associated with promoters of actively transcribed genes, trimethylation of histone H3 at lysine 4 (H3K4me3) is a core histone mark set by several protein complexes. Some of these protein complexes contain the trithorax protein ASH2 combined with the MLL oncoproteins. We identified human ASH2 in a complex with the oncoprotein MYC. This finding, together with the observation that hASH2 interacts with MLL, led us to test whether hASH2 itself is involved in transformation. We observed that hASH2 cooperates with Ha-RAS to transform primary rat embryo fibroblasts (REF). Furthermore, transformation of REFs by MYC and Ha-RAS required the presence of rAsh2. In an animal model, the hASH2/Ha-RAS–transformed REFs formed rapidly growing tumors characteristic of fibrosarcomas that, compared with tumors derived from MYC/Ha-RAS transformed cells, were poorly differentiated. This finding suggests that ASH2 functions as an oncoprotein. Although hASH2 expression at the mRNA level was generally not deregulated, hASH2 protein expression was increased in most human tumors and tumor cell lines. In addition, knockdown of hASH2 inhibited tumor cell proliferation. Taken together, these observations define hASH2 as a novel oncoprotein. [Cancer Res 2008;68(3):749–58]